Steven Pergam

Adjunct Associate Professor, Epidemiology
Associate Professor, Medicine - Allergy and Infectious Dis.



MD University of Nebraska, 1998
MPH Epidemiology, University of Washington, 2008



Fred Hutchinson Cancer Research Center
Box 358080
1100 Fairview Ave. N, E4-100
Seattle, WA 98109
View Website »


Dr. Pergam is an Infectious Diseases physician and researcher who received his MD from the University of Nebraska School of Medicine, his Infectious Diseases fellowship training at the University of Washington (UW), and his MPH from the UW School of Public Health. Dr. Pergam serves as the Medical Director of Infection Prevention at the Seattle Cancer Care Alliance (SCCA). Dr. Pergam focuses his research on the prevention and treatment of infections among immunocompromised patients, and has expertise in infection prevention and hospital epidemiology among cancer and transplant patients. He serves on numerous national committees, including the CDC’s Advisory Committee on Immunization Practices, and the National Comprehensive Cancer Network Committee on the Prevention and Treatment of Infections in Cancer. He also is an Associate Editor for BMC Infectious Diseases and Current Opinions in Infectious Diseases.

Research Interests

Dr. Pergam’s research interests involve hospital epidemiology, antimicrobial resistance, and infection prevention in immunosuppressed hosts. His research group focuses on infection prevention, resistant pathogens, antimicrobial stewardship, and on the development of novel prevention strategies for community and healthcare-associated infections in cancer and hematopoietic cell transplant patients. He has active research projects that evaluate vaccinations, water-borne pathogens, resistant bacteria, respiratory virus transmission, and fungal infections among immunocompromised hosts. He is interested in the interplay between the immune response, the microbiome, bacterial and viral infections in the respiratory and gastrointestinal systems, and their association with inflammatory complications (e.g. Graft-versus-host disease, mucositis).

Recent Publications (PubMed)

Invasive Fungal Infections After CLAG-M/CLAG Chemotherapy for Acute Myeloid Leukemia and High-Grade Myeloid Neoplasms.
(2023 Feb 15)
Blood Adv
Lindsay J, Walti CS, Halpern AB, Xie H, Chung EL, Schonhoff KG, Huebner EM, Cheng GS, Kimball L, Leisenring WM, Greenwood M, Chen SC, Kong DC, Slavin MA, Boeckh M, Fredricks D, Liu C, Pergam SA, Walter RB, Hill JA

Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
(2023 Feb)
Leukemia 37(2): 298-307
Walti CS, Halpern AB, Xie H, Kiem ES, Chung EL, Schonhoff KG, Huebner EM, Delaney C, Liu C, Pergam SA, Cheng GS, Kimball LE, Leisenring WM, Boeckh M, Walter RB, Hill JA

Antibiotic prescribing knowledge: A brief survey of providers and staff at an ambulatory cancer center during Antibiotic Awareness Week 2019.
Antimicrob Steward Healthc Epidemiol 2(1): e18
Gulleen EA, Krantz EM, Zier J, Bhattacharyya P, Kates O, So L, Sweet A, Yoke LH, Pergam SA, Liu C

Frequently Asked Questions on Coronavirus Disease 2019 Vaccination for Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Recipients From the American Society for Transplantation and Cellular Therapy and the American Society of Hematology.
(2023 Jan)
Transplant Cell Ther 29(1): 10-18
Khawaja F, Papanicolaou G, Dadwal S, Pergam SA, Wingard JR, Boghdadly ZE, Abidi MZ, Waghmare A, Shahid Z, Michaels L, Hill JA, Kamboj M, Boeckh M, Auletta JJ, Chemaly RF

Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant.
(2022 Dec)
Bone Marrow Transplant 57(12): 1765-1773
Ogimi C, Krantz EM, Golob JL, Liu C, Waghmare A, Akramoff A, Mallory A, Leisenring WM, Jerome KR, Chow VA, Pergam SA, Fredricks DN, Englund JA, Boeckh M

Show complete publication list